- Home
- WDH vs LRMR Comparison
WDH vs LRMR Comparison
Compare WDH & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WDH | LRMR |
|---|---|---|
| Founded | 2016 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 416.8M | 455.8M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | WDH | LRMR |
|---|---|---|
| Price | $1.12 | $4.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 140.9K | ★ 2.6M |
| Earning Date | 06-04-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.57% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.71 | $1,816.14 |
| P/E Ratio | $9.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.08 | $2.72 |
| 52 Week High | $2.18 | $6.42 |
Technical Indicators
Market Signals| Indicator | WDH | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 33.71 | 60.14 |
| Support Level | $1.10 | $3.87 |
| Resistance Level | $1.32 | $4.32 |
| Average True Range (ATR) | 0.04 | 0.28 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 3.55 | 78.83 |
Price Performance
Historical ComparisonAbout WDH Waterdrop Inc. (each representing the right to receive 10)
Waterdrop Inc is a technology platform dedicated to insurance and healthcare service. The Company is mainly engaged in operating an independent third-party insurance platform dedicated to providing insurance and healthcare service. The Companies main businesses are the insurance marketplace, medical crowdfunding, and mutual aid. The companies reportable segments are Insurance, Crowdfunding and Others.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.